Quick Summary — SPRY scores higher on quality with 4.7/10 vs SNTI's 4.1/10. SNTI trades at $0.98 while SPRY trades at $8.90. Both analyzed daily using SEC EDGAR data across 13 institutional models.
SPRY scores higher with a 4.7/10 quality rating vs SNTI's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $0.98, SNTI trades +48.4% above its Bayesian DCF fair value of $0.52, while SPRY at $8.90 trades +76.5% above its estimate of $2.09. SPRY shows a wider gap between price and intrinsic value.
SNTI earns a Quality of Company score of 4.1/10 compared to SPRY's 4.7/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
SNTI carries a LOW value trap risk (39/100) while SPRY shows SAFE risk (24/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both SNTI and SPRY operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare SNTI vs SPRY differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.